

Usage of Topical Therapies in the Management of Oral Lichen Planus

Haripriya R, Jayanth Kumar Vadivel*

Department of Oral Medicine, Saveetha University, Chennai, India

INTRODUCTION

INTRODUCTION

Oral Lichen Planus is a mucocutaneous chronic inflammatory condition with cell mediated immunological dysfunction. It implicates T cell mediated cytotoxins and involves the mucosal surfaces. Topical formulations are the favourite for majority of cases, adhesive formulations have been considered very useful and practical for local drug delivery in oral mucosa.

AIM

The aim of the present study is to analyse the usage of topical therapies in the management of oral lichen planus.

MATERIALS AND METHODS

The study was done in a hospital setting. The data was collected from the patient software system of Saveetha Dental College and the samples included patients treated with oral therapies for oral lichen planus. The data collected was tabulated and statistically analysed using SPSS software. The results were tabulated and graphically represented.

RESULTS

Among the oral drugs prescribed, corticosteroids was the most commonly prescribed drug among which tacrolimus was the most commonly prescribed drug.

KEYWORDS

Vitiligo, Chronic autoimmune skin disease, Dermatology

Corresponding Author:

*Jayanth Kumar Vadivel,
Department of Oral Medicine,
Saveetha University, Chennai,
India; Email: jdoctorjayanth@gmail.
com*

How to Cite This Article:

*Haripriya R, Vadivel JK. Usage of
Topical Therapies in the
Management of Oral Lichen
Planus. J Evid Based Med Healthc
2022;9(06):30.*

*Received date: 08-March-2022;
Manuscript No: JEBMH-22-50956;
Editor assigned date: 11-March-2022;
PreQC No. JEBMH-22-50956(PQ);
Reviewed date: 25-March-2022;
QC No. JEBMH-22-50956;
Revised: 30-March-2022;
Manuscript No. JEBMH-22-50956;
Published date: 05-April-2022;
DOI: 10.18410/jebmh/2022/09.06.30*

*Copyright © 2022 Haripriya R, et al
This is an open access article
distributed under Creative
Commons Attribution License
[Attribution 4.0 International (CC BY
4.0)]*

INTRODUCTION

Oral lichen planus is a chronic inflammatory mucocutaneous condition. The disease occurs first in the oral mucosa and then it manifests in the skin.¹ It is implicated by an antigen specific mechanism activating T cell-mediated cytotoxicity and non-specific mechanisms like mast cell degranulation and matrix metalloproteinase activation.² Off late there has been several studies pointing to the role of the mast cells. It may be the mast cells which is responsible for the persistence of the lesions.³ It affects the oral mucosal membrane with stratified squamous epithelium.⁴⁻⁶ Though the exact etiology is unknown. But there are definitive risk factors like genetic background, infectious agents, dental materials, stress, trauma, habits, systemic diseases, etc. are associated with it.⁵⁻¹¹ The disease is characterized by lesions with radiating white, velvety, grey, papules that resemble thread in a linear pattern, annular and reform arrangement forming typical lacy, reticular patches, rings and streaks.¹² The lesions are usually asymptomatic. The lesions occur mostly on buccal mucosa, lips, tongue, gingiva, floor of mouth and palate.¹³ The oral lichen planus has six clinical presentations. They are reticular, bullous, plaque like, erosive, atrophic, papular.^{6,13}

Biopsy is often helpful in the diagnosis of oral lichen planus. Patient's physiological profile and medical history play an important role in the effectiveness of OLP treatment. The first line of treatment for oral lichen planus includes topical administration of the drug as it is the most suitable and effective of all treatment modalities.¹⁴ Topical administration of drugs on the lesion is found to be the most successful on oral soft tissues. Corticosteroids and immunosuppressants are the most commonly prescribed drugs for topical treatment of oral lichen planus.^{14,15}

The goal of lichen planus treatment is to relieve pain and to reduce the signs and symptoms. The current treatment modalities are palliative than curative and recurrence usually occurs.¹³

Our team has extensive knowledge and research experience that has translate into high quality publications.¹⁶⁻³⁵ The aim of this study is to evaluate the different topical drugs used in the management of oral lichen planus

MATERIALS AND METHODS


The present study was done under a university setting. The similar characteristics of the study are that it was done with the available data and under similar ethnicity of the population. The disadvantage of the study can be the geographic isolation. The study was approved by the


Institutional Ethics Board. This was a retrospective cross sectional study. The samples include patients with oral lichen planus who underwent topical therapy. To minimize error, the duplicate and invalid records were excluded. The internal validity included convenience sampling and the external validity of the study is questionable when considered for the entire population. The data collection was done from the dental archives of the patient management software system patented by Saveetha Dental College. If invalid or duplicate records were entered, they were excluded from the study. The data was reviewed by an external reviewer and tabulated using

Excel and was imported to SPSS (version 26) and the variables were defined. The independent variables included the gender, age and site. The dependent variable included the drugs for treatment of lichen planus. Chi square test and Pearson correlation was done on the data obtained using SPSS software.


RESULTS

In the present study, a total of 106 patients were involved among which 43 patients (40.6 %) were male patients and 63 patients (59.4 %) were female patients. (Graph 1) Among the 106 patients, 3 patients (2.8 %) were below 20 years, 10 patients (9.4 %) were 21- 30 years, 24 patients (22.6 %) were 31 - 40 years, 26 patients (24.5 %) were 41 - 50 years, 43 patients (41.6 %) were above 50 years. Oral lichen planus was more prevalent in elderly patients (Graph 2).






It was found that corticosteroids were the most commonly prescribed drug for lichen planus (78 %) followed by anti-fungal drugs (52 %) and steroid sparing Immunomodulatory drugs (20 %) Among corticosteroids, triamcinolone was the most commonly prescribed drug especially in elderly patients (27.7 %) followed by combination of triamcinolone and betamethasone drugs (14.46 %), and clobetasol was prescribed only in elderly patients (1.2 %). In young patients (below 20 years), only triamcinolone (1.2 %) and betamethasone (1.2 %) was prescribed for patients at the age of 30 - 40 years. In patients between 31 - 40 years, triamcinolone (12.05 %), betamethasone (1.2 %) and combination of triamcinolone and betamethasone (8.43%) were prescribed. In all age groups, triamcinolone was the most commonly prescribed drug in corticosteroids (Graph 3).




In antifungal drugs, Clotrimazole was the commonly prescribed drug. In elderly patients, 37.5 % were prescribed, in patients between 41 - 50 years, 23.2 % were prescribed with Clotrimazole, in patients between 31 - 40 years, 26.7 % were prescribed, in 21 - 30 years patients, 7.14 % were prescribed and

in younger patients, below 20 years, 5.36 % were prescribed with Clotrimazole (Graph 4).



In steroid sparing immunomodulator drugs, dapsone was prescribed for younger patients ie below 20 years (4.55 %) while the adult patients were prescribed with tacrolimus (Graph 5).



DISCUSSION

Corticosteroids were the predominant drugs used in the management of OLP. This is primarily because the disease has an immune mediated reaction and there is an exaggerated immune response which may be triggered. The usage of steroids suppress the inflammation and reduces the recruitment of inflammatory cells to the site of the lesion.¹³ In a study comparing the effectiveness of steroids and hyaluronic acid it was found that steroids brought out a quicker resolution of the lesion as evidenced by the reduction of lesion size and reduction in pain score. This study which evaluated the effectiveness of steroids and hyaluronic acid was a double blind randomized control trial.³⁶

In a study done to assess the therapeutic Effectiveness of clobetasol propionate 0.01 % there were three different vehicles used for dispensing the drug. The first vehicle was an ointment the second vehicle was clobetasol propionate in rebase which contained benzocaine and the third vehicle was clobetasol propionate in denture adhesive base. This study was a randomized controlled double blind control study. There were a total of 24 patients with 8 patients in each group. The pain scores returned to a early in the or abase group compared to the other two groups.³⁷

The usage of antifungal is double pronged as any mucosal abnormality is bound to the causation of candida colonizing the mucosal surface and the usage of anti-fungal is bound to reduce the colonization. Also the usage of antifungals causes a reduction in the occurrence of secondary candidiasis which tends to co-occur with the usage of steroids.³⁸

The usage of tacrolimus has been associated with its role in reducing the inflammation without the adverse effects of steroids. Also the drugs can cause a reduction in the number of mast cells and there by brings out a resolution of the lesion.³⁹

CONCLUSION

From the present study we can conclude that corticosteroids were the most commonly prescribed topical drug for oral lichen planus among which tacrolimus was commonly prescribed followed by antifungal drug (clotrimazole) and steroid sparing immunomodulator drugs were the least prescribed. However the sample size is smaller and it is a unicentric study. A metacentric trial needs to be adopted to ensure that an effective conclusion can be made.

REFERENCES

- Lodi G, Giuliani M, Majorana A, et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. *Br J Dermatol* 2004;151(6):1172 –1181.
- Vadivel JK, Ezhilarasan D, Govindarajan M, et al. Therapeutic effectiveness of alternative medications in oral lichen planus: A systematic review. *J Oral Maxillofac Pathol* 2020;24(2):344–351.
- Vadivel JK, Govindarajan M, Somasundaram E, et al. Mast cell expression in oral lichen planus: A systematic review. *J Investig Clin Dent* 2019;10(4):275.
- Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. *Clin Dermatol* 2010;28:100–108.
- Eisenberg E. Oral lichen planus: a benign lesion. *J Oral Maxillofac Surg* 2000;58(11):1278–1285.
- Canto AM do, Muller H, Freitas RR de, et al. Oral lichen planus (OLP): clinical and complementary diagnosis. *An Bras Dermatol* 2010;85(5):669–675.
- Sun A, Hsieh RP, Liu BY, et al. Strong association of antiepithelial cell antibodies with HLA-DR3 or DR7 phenotype in patients with recurrent oral ulcers. *J Formos Med Assoc* 2000;99(4):290–294.
- Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. *Br J Oral Maxillofac Surg* 2008;46(1):15–21.
- Scully C, Beyli M, Ferreiro MC, et al. Update On Oral Lichen Planus: Etiopathogenesis and Management. *Crit Rev Oral Biol Med* 1998;9:86–122.
- Issa Y, Brunton PA, Glennly AM, et al. Healing of oral lichenoid lesions after replacing amalgam restorations: a systematic review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2004;98(5):553–565.
- Razavi G, Moravvej H, Hoseini H, et al. Association of *Helicobacter pylori* with lichen planus. *Indian J Dermatol* 2007;52:138.
- Rajendran R. Shafer'S Textbook of Oral Pathology (6Th Edition). Elsevier India; 2009.
- Radwan-Oczko M. Topical application of drugs used in treatment of oral lichen planus lesions. *Adv Clin Exp Med* 2013;22(6):893–898.
- Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. *Macromol Biosci* 2011;11(6):748–764.
- McGrath C, Hegarty AM, Hodgson TA, et al. Patient-centred outcome measures for oral mucosal disease are sensitive to treatment. *Int J Oral Maxillofac Surg* 2003;32:334–6.
- Jayasree R, Kumar PS, Saravanan A, et al. Sequestration of toxic Pb(II) ions using ultrasonic modified agro waste: Adsorption mechanism and modelling study. *Chemosphere*. 2021;285:131502.
- Sivakumar A, Nalabothu P, Thanh HN, et al. A Comparison of Craniofacial Characteristics between Two Different Adult Populations with Class II Malocclusion-A Cross-Sectional Retrospective Study. *Biol* 2021;10(5).
- Uma Maheswari TN, Nivedhitha MS, Ramani P. Expression profile of salivary micro RNA-21 and 31 in oral potentially malignant disorders. *Braz Oral Res* 2020;34:e002.

19. Avinash CKA, Tejasvi MLA, Maragathavalli G, et al. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. *Indian J Pathol Microbiol* 2020;63:538.
20. Chaitanya NC, Muthukrishnan A, Rao KP, et al. Oral Mucositis Severity Assessment by Supplementation of High Dose Ascorbic Acid During Chemo and/or Radiotherapy of Oro-Pharyngeal Cancers--A Pilot Project. *Indian J Pharm Educ Res* 2018;52(3):532–539.
21. Gudipani RK, Alam MK, Patil SR, et al. Measurement of the Maximum Occlusal Bite Force and its Relation to the Caries Spectrum of First Permanent Molars in Early Permanent Dentition. *J Clin Pediatr Dent* 2020;44(6):423–428.
22. Chaturvedula BB, Muthukrishnan A, Bhuvaraghan A, et al. Dens invaginatus: a review and orthodontic implications. *Br Dent J* 2021;230(6):345–350.
23. Patil SR, Maragathavalli G, Ramesh DNS, et al. Assessment of Maximum Bite Force in Pre-Treatment and Post Treatment Patients of Oral Submucous Fibrosis: A Prospective Clinical Study. *J Hard Tissue Biol* 2021;30:211–6.
24. Ezhilarasan D, Apoorva VS, Ashok Vardhan N. Syzygium cumini extract induced reactive oxygen species-mediated apoptosis in human oral squamous carcinoma cells. *J Oral Pathol Med* 2019;48(2):115–21.
25. Sharma P, Mehta M, Dhanjal DS, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. *Chem Biol Interact* 2019;309:108720.
26. Perumalsamy H, Sankarapandian K, Veerappan K, et al. In silico and in vitro analysis of coumarin derivative induced anticancer effects by undergoing intrinsic pathway mediated apoptosis in human stomach cancer. *Phytomedicine* 2018;46:119–130.
27. Rajeshkumar S, Menon S, Venkat Kumar S, et al. Antibacterial and antioxidant potential of biosynthesized copper nanoparticles mediated through *Cissus arnotiana* plant extract. *J Photochem Photobiol B* 2019;197:111531.
28. Mehta M, Dhanjal DS, Paudel KR, et al. Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update. *Inflammopharmacology*. 2020;28(4):795–817.
29. Rajakumari R, Volova T, Oluwafemi OS, et al. Nano formulated proanthocyanidins as an effective wound healing component. *Mater Sci Eng C Mater Biol Appl* 2020;106:110056.
30. PradeepKumar AR, Shemesh H, Nivedhitha MS, et al. Diagnosis of Vertical Root Fractures by Cone-beam Computed Tomography in Root-filled Teeth with Confirmation by Direct Visualization: A Systematic Review and Meta-Analysis. *J Endod* 2021;47(8):1198–1214.
31. Ramani P, Tilakaratne WM, Sukumaran G, et al. Critical appraisal of different triggering pathways for the pathobiology of pemphigus vulgaris-A review. *Oral Dis* 2021.
32. Ezhilarasan D, Lakshmi T, Subha M, et al. The ambiguous role of sirtuins in head and neck squamous cell carcinoma. *Oral Dis* 2021.
33. Sarode SC, Gondivkar S, Sarode GS, et al. Hybrid oral potentially malignant disorder: A neglected fact in oral submucous fibrosis. *Oral Oncol* 2021:105390.
34. Kavarthapu A, Gurumoorthy K. Linking chronic periodontitis and oral cancer: A review. *Oral Oncol* 2021;105375.
35. Preethi KA, Lakshmanan G, Sekar D. Antagomir technology in the treatment of different types of cancer. *Epigenomics* 2021;13(7):481–484.
36. Hashem AS, Issrani R, Elsayed TEE, et al. Topical hyaluronic acid in the management of oral lichen planus: A comparative study. *J Investig Clin Dent* 2019;10(2):e12385.
37. Lo Muzio L, della Valle A, Mignogna MD, et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. *J Oral Pathol Med* 2001;30(10):611–617.
38. Arora S, Verma M, Gupta SR, et al. Phenotypic variability and therapeutic implications of *Candida* species in patients with oral lichen planus. *Biotech Histochem* 2016;91(4):237–241.
39. Byrd JA, Davis MDP, Bruce AJ, et al. Response of oral lichen planus to topical tacrolimus in 37 patients. *Arch Dermatol* 2004;140(12):1508–1512.